Nektar seeks CEO
Nektar Therapeutics has formed a CEO search committee to appoint a successor to replace chief exec Ajit Gill, who will retire March 17. Gill announced his resignation following the approval of the inhaled insulin treatment Exubera, for which Nektar developed the inhaler. Approval marks an "appropriate time to bring in a new CEO to lead Nektar in its next phase of growth to a more products-focused drug delivery company," firm says. Executive Chairman and former CEO Robert Chess will serve as acting CEO following Gill's departure...
You may also be interested in...
Cosmetics Europe Talks Microplastic: ECHA Frustrations, ‘Value Judgments’ And International Trade Uncertainty
The European Chemicals Agency's microplastic restriction proposal received committee backing in 2020 without changes sought by the cosmetics industry, which faces €15bn in projected costs and scarce alternatives at present. It may come down to EU Member States to decide whether the ECHA restriction proposal is proportionate in balancing environmental goals and socio-economic impacts.
Roche/Genentech oncology partnering maintained a robust dealmaking pace through the pandemic, keeping the percentage of partnered R&D programs at about 50% of the cancer drug pipeline.
To mitigate pandemic disruption of component supply chains, the US FDA said it will downgrade some post-approval change categories for sterile drug container closure systems. The downgrade will cover drugs in shortage and those used to treat COVID-19.